NYSEHealth CareMedical Care FacilitiesSnapshot 2026-07-23
Reading CHE? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This is a long-term thesis on a company that is currently loss-making but has stable management and strong recent financial performance. The thesis is intact, but it is sensitive to sector dynamics.
The market currently reflects a neutral valuation for CHE, with expectations slightly below its peers. There is a low fragility tier, indicating that the stock is not overly sensitive to negative news at this time.
Management has made progress on increasing revenue growth and has raised earnings per share (EPS) guidance for 2026. However, there is a moderate risk of missing earnings expectations, as recent trends show a downward trajectory in earnings surprises.
The future performance of CHE hinges on the actions of sector bellwethers like HCA, THC, and DVA. If these companies continue to perform well, it could support CHE's growth; however, any negative guidance from them could adversely affect CHE.
In the next 1 to 3 years, CHE's performance will depend on both its internal execution and the broader healthcare sector's health. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement, indicating that the company's financial performance remains strong. There are no current threats identified that could weaken this positive outlook.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: If VITAS meets or beats its new revenue growth goal, it shows recovery. This is important for the company's overall performance.
Confirms:VITAS revenue growth excluding Medicare Cap exceeds 6.5% in the next quarter.
Disproves:VITAS revenue growth excluding Medicare Cap falls below 6.5%.
Why it matters: An increase shows stronger earnings potential. It also suggests a positive outlook from management.
Confirms:EPS guidance exceeds $24.75 for 2026.
Disproves:EPS guidance remains below $24.00 for 2026.
Why it matters: Higher EPS guidance shows management believes in earnings growth. This can help how investors feel.
Confirms:EPS guidance is raised above the current range of $24.00 to $24.75.
Disproves:EPS guidance remains unchanged or is lowered.
Why it matters: If Roto-Rooter meets its revenue growth goal, it shows good management of challenges.
Confirms one read:Roto-Rooter revenue growth meets or exceeds the guidance of 3.0% to 3.5%.
Confirms the other:Roto-Rooter revenue growth falls below 3.0%.
